LAight® Therapy Improves Hidradenitis Suppurativa in Patients Declining Surgical Intervention: Two Case Reports

Izak Johannes BISSCHOFF¹, Daniela KASCHE¹, Uwe KIRSCHNER², Piotr K. KRAJEWSKI¹, Łukasz MATUSIAK³ and Jacek C. SZEPIEWSKI¹

¹Dermatology Outpatient Office Dr Daniela Kasche, Hamburg, ²Dermatology Outpatient Office Dr Uwe Kirschner, Mainz, Germany, and ³Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Chalubinskiego 1, PL-50-368 Wroclaw, Poland. E-mail: jacek.szepietowski@umed.wroc.pl

Accepted Jun 4, 2020; Epub ahead of print Jun 9, 2020

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by nodular inflammation, abscesses, fistulas and pus discharge, mainly located in the intertriginous areas of the skin (1). Considerably reduced quality of life (QoL) in patients with HS has been well documented (2). In recent years, new medical treatment modalities for HS have emerged (3). However, the guidelines and the treatment algorithms highlight the necessity for surgical interventions, especially in patients with Hurley stages II and III HS (4). The Mandatory Surgical Indications According to Bechara for Hidradenitis Suppurativa Surgery (MIBHS) has been presented recently. MIBHS include fistulas/sinus tracts, accordion-like scars, contracted scars, mutilating HS and suspected malignancy (5). However, patients are often reluctant to undergo surgery.

In 2017, LAight® therapy (LENICURA, Wiesbaden, Germany), a non-invasive, device-based treatment utilizing a combination of intense pulsed light (IPL) and radiofrequency (RF), was approved throughout the European Union (EU) for all severities of HS (https://www.lenicura.com/laight-therapy). LAight® therapy comprises 3 treatment passes differing with respect to applied IPL pulses. Detailed technical data are shown in Table I (6). The treatment is beneficial for patients, with improvements in skin lesions and QoL (6). We report here 2 additional patients with HS who declined surgical procedures, but improved markedly with LAight® therapy.

CASE REPORTS

Case 1. A 39-year-old Caucasian woman presented with Hurley stage II disease with lesions located on both axillae, the groins and the buttocks (Fig. 1A). The patient had previously undergone several incisions, drainage procedures and 2 additional excisions with primary closures. These resulted in temporary improvement; however, they recurred after a few years.

On admission, the patient’s QoL was substantially impaired (Dermatology Life Quality Index (DLQI) score 17 points) and the pain intensity, evaluated on an 11-point numeral rating scale (NRS), was 6 points.

Taking all the above into consideration, the patient underwent LAight® monotherapy every second week. After 10 treatments, her condition had improved considerably, especially the inflammation, which reduced significantly. The DLQI score decreased to 4 points; however, the intensity of pain remained at a similar level (NRS 5 points). The patient continued the therapy, and after 24 additional consecutive sessions the inflammatory lesions were almost eliminated. DLQI was assessed as 2 points, and the pain level decreased to 3 points. The scarring process remained unchanged. However, the patient reported softening of the scars (Fig. 1B).

Case 2. A 32-year-old Caucasian man presented with Hurley stage II HS with lesions in both axillae, the suprapubic area and the buttocks. He had previously undergone numerous incisions, drainage procedures and simultaneous excisions of 30 cm² from each axilla. However, the disease progressed (Fig. 2A). The patient declined further surgical interventions. On admission, the patient’s DLQI was 6 points and he assessed his pain intensity with the NRS as 6 points.

The patient began LAight® therapy on a regime of every second week. After 10 treatment sessions, his inflammation and scar texture improved. This resulted in a marked improvement of the patient’s QoL. The DLQI score decreased to the level of 1 point, indicating normal QoL. In addition, the pain intensity reduced to 3 points. After a total of 34 treatment sessions, this therapy resulted in almost complete reduction of inflammation, and pain (NRS=0 points), and marked softening of the scars (in the patient’s opinion) (Fig. 2B). At this time, the patient’s DLQI was 1 point.

DISCUSSION

Standard treatment options for HS involve both the conservative and the surgical approach (7). Surgery is considered the only effective treatment option, as conservative therapy does not cure irreversible skin tissue damage caused by HS (4, 5). Based on our experience and available literature data, many patients decline radical surgical interventions (8). We believe that a non-invasive approach (e.g. LAight® therapy) could be a promising alternative for this group of HS patients.

Previously it was indicated that monotherapy with IPL reduced inflammation in patients with HS (9). Moreover, it is also known that RF may stimulate collagen remodelling, leading to improvement in the texture of the scars (10, 11). It was suggested that IPL blue light has anti-inflammatory properties via

### Table I. Technical characteristics of LAight® therapy (6)

| RF Intensities (J/cm²) | RF Impulse Characteristics | IPL Wavelength Interval (nm) | IPL Intensities (J/cm²) | IPL Impulse Characteristics |
|------------------------|---------------------------|-------------------------------|--------------------------|----------------------------|
| 1st treatment pass     | One impulse of 1 MHz frequency and 1 s duration | 420–1,200 | 6.0 | 4 sub-impulses: 8 ms/8 ms (duration/pause) |
| 2nd treatment pass     | One impulse with 1 s duration and frequency of 1 MHz | 510–1,200 | 5.6 | 4 sub-impulses: 8 ms/8 ms (duration/pause) |
| 3rd treatment pass     | One impulse with 1 s duration and frequency of 1 MHz | 690–1,200 | 4.4 | 4 sub-impulses: 8 ms/8 ms (duration/pause) |

This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta

Acta Derm Venereol 2020; 100: adv00193
doi: 10.2340/00015555-3558

Acta Derm Venereol 2020; 100: adv00193
reduction of IL-1α and ICAM-1 (2). Furthermore, superficial desquamation of the epidermis might reduce hair follicle blockage, which is one of the major initial causes of development of HS (2). A positive effect on HS might also be that RF mediates liquefaction of enclosed lipids, releasing blockage of the hair follicles (4). In addition, a synergetic effect of the 2 components was supported by Seok et al. (12), who analysed the effect of RF and IPL in an acne-induced rabbit ear model. In combination, the 2 had an additive effect in treatment (5).

This has been confirmed recently by the study by Wilden et al. (6) dealing with 47 subjects with HS. They showed that combined IPL+RF treatment (Laight®) was superior to the monotherapy of both IPL and RF. After 12 weeks of therapy, they reported a 10% reduction in count of active lesions among patients treated with IPL+RF, compared with a 5% reduction with RF, and 6% increase with IPL monotherapies. The effectiveness of the combined therapy was more prominent for patients with Hurley I/II stage compared with Hurley III stage, resulting in reductions in the number of active lesions of 32% and 2%, respectively (6). The analysis of DLQI score reduction (between week 0 and week 12) in the 3 different treatment arms revealed that the decrease in DLQI was much less pronounced in the RF group (mean change –1.3 points) compared with the IPL group (mean –5.1 and –6.6; respectively), which achieved the level of minimal clinically important difference (MCID) (13). The MCID (reduction of at least 4 points) in DLQI scores (14) was also achieved in both of the current patients. We found a 15-point reduction in the first subject and a 5-point reduction in the second. A similar effect was obtained for pain assessed with NRS. Both of the patients reported a substantial decrease in pain intensity (3 points), indicating achievement of MCID for reduction in NRS pain intensity (15).

In conclusion, Laight® therapy could be beneficial for patients with HS, especially those who are reluctant to undergo surgical procedures. It is well tolerated; no adverse effects were observed. Laight® therapy can be used as monotherapy, but it might also be combined with both topical and/or systemic agents. Particular attention should be paid to the combination of Laight® therapy with resorcinol, as Theut Riis et al. (16) reported an increased risk of adverse events after treatment with a combination of IPL and resorcinol. Moreover, it is also clear that systemic tetracycline should be used with any light treatment (16). Further research studies are required into the combined therapies.

REFERENCES

1. Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis suppurativa/acute inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 2015; 231: 184–190.
2. Matusiak L, Bieniek A, Szepeitowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 2010; 62: 706–708.
3. Wlodarek K, Ponikowska M, Matusiak L, Szepeitowski JC. Biologics for hidradenitis suppurativa: an update. Immuno-therapy 2019; 11: 45–59.
4. Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horvath B, Hughes R, et al. Hidradenitis suppurativa/acute inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol 2019; 33: 19–31.
5. Bechara FG, Hassam S. Ständig entzündliche Knoten und Abszesse in Achsel und Leiste. MMW Fortschr Med 2016; 158: 52–53.
6. Wilden S, Friis M, Tuuttenberg A, Staubach-Renz P, Wegner J, Grabbe S, et al. Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). J Dermatolog Treat 2019 Oct 17 [Epub ahead of print].
7. Zouboulis CC, Desai N, Emmetstam L, Hunger RE, Ioannides D, Juhazs I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acute inversa. J Eur Acad Dermatol Venereol 2015; 29: 619–644.
8. Janse I, Bieniek A, Horvath B, Matusiak L. Surgical procedures in hidradenitis suppurativa. Dermatol Clin 2016; 34: 97–109.
9. Highton L, Chan WY, Khwaja N, Laitung JK. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg 2011; 128: 459–465.
10. Hamzavi IH, Griffith JL, Riyaz F, Hassam S, Bechara FG. Laser and light-based treatment options for hidradenitis suppurativa. J Am Acad Dermatol 2015; 73: 578–581.
11. Iwasaki J, Marra DE, Fincher EF, Moy RL. Treatment of hidradenitis suppurativa with a nonablative radiofrequency device. Dermatol Surg 2008; 34: 114–117.
12. Seok J, Kim JH, Kim JM, Kwon TR, Choi SY, Li K, Kim BJ. Effects of intradermal radiofrequency treatment and intense pulsed light therapy in an acne-induced rabbit ear model. Sci Rep 2019; 9: 5056.
13. Cook CE. Clinimetrics Corner: The Minimal Clinically Important Change Score (MCID): a necessary pretense. J Man Manip Ther 2008; 16: E82–E83.
14. Basra MK, Salek MS, Camilleri L, Starkey R, Finlay AW. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27–33.
15. Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, et al. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med 2017; 15: 35.
16. Theut Riis P, Saunte DM, Sigsgaard V, Wilken C, Jemec GB. Intense pulsed light treatment for patients with hidradenitis suppurativa: beware treatment with resorcinol. J Dermatolog Treat 2018; 29: 385–387.